Reportedly, there is now a multidistrict litigation under a single judge’s supervision in Illinois regarding the safety of the medication Pradaxa. Claims, which will be heard in the U.S. District Court in the Southern District of Illinois, are seeking compensation for medical costs and expenses tied to internal bleeding that allegedly resulted from using Pradaxa. According to the court docket, the number of Pradaxa product liability lawsuits claiming problems with internal bleeding has already reached 260 cases.
Pradaxa is a blood thinner used to protect against heart attacks and strokes. However, many claim that it caused internal bleeding problems that may have led to brain hemorrhages and heart attacks and that the company failed to adequately warn patients and health care professionals about the potential side effects of the drug. Boehringer Ingelheim, the manufacturer of Pradaxa, denies the claims filed against them, including the negligence claim.
Reportedly, Pradaxa gained FDA approval in 2010 for patients who were at risk for atrial fibrillation as an improvement over the Warfarin brand, Coumadin, another blood thinner. However, some plaintiffs claim that while an antidote for Warfarin exists, Pradaxa has no antidote and deaths have occurred in some cases. Bloomberg News reported that “Concerns about Pradaxa’s safety surfaced soon after U.S. doctors began prescribing it. FDA officials said they received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.”
According to the court file, Pradaxa plaintiffs are seeking financial compensation for medical costs and expenses, wrongful deaths, and pain and suffering. Though the plaintiffs are scattered across the country, the purpose of bringing them together in a multidistrict litigation under a single judge is for legal procedures and pre-trial evidence gathering.
In most cases, it is not too late for other individuals who suffered internal bleeding or other side effects after taking Pradaxa to file a product liability lawsuit under this multi-district litigation. Currently no order prohibiting additional Pradaxa claims has been issued by the judge. Furthermore, the judge’s most recent ruling allowed lawyers for plaintiffs to be granted document access they had requested, an indication that there is still time to file claims before trial.